Article Information
History
- January 21, 2023.
Article Versions
- You are currently viewing Version 1 of this article (January 21, 2023 - 00:09).
- Version 2 (March 2, 2023 - 11:25).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- aSchool of Life Sciences, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, People’s Republic of China
- bInstitute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China
- cBeijing Intelligent Medicine and Network Pharmacology Co., Ltd, Beijng 100020, China
- dShanghai Applied Protein Technology Co., Ltd., 58 Yuanmei Road, Shanghai 200233, People’s Republic of China
- eTianjin Key Laboratory of Medical Mass Spectrometry for Accurate Diagnosis, Tianjin 300399, People’s Republic of China
- ↵*Address correspondence to Jun Kang, jun.kang{at}tju.edu.cn; or Peiyuan Liu, peiyuan.liu{at}tju.edu.cn; or Wenbo Cheng, chengwb{at}sibet.ac.cn.
↵1 Jianying Song and Bo Zhang contributed equally to this work. Author order was determined on the basis of seniority.
Posted January 21, 2023.
Quantitative proteomics combined with network pharmacology analysis unveils the biological basis of Schisandrin B in treating diabetic nephropathy
